Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Monte Rosa reported that one of its molecular glue degraders had seen a strong response in immune disorders, but another fell ...

Wedbush raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $17 from $15 and keeps an Outperform rating on the shares after the ...

BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ: GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading.

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

Also in October 2024, Novartis joined its fellow industry heavy hitters with a $150 million upfront payment to Monte Rosa Therapeutics, gaining access to the Boston biotech’s molecular glue degraders ...

Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in ...